Navigation Links
MAP Pharmaceuticals to Present Data Showing Low Migraine Recurrence Rates With LEVADEX™ in FREEDOM-301 Trial
Date:10/29/2010

amine (DHE), a drug used intravenously in clinical settings to effectively and safely treat migraines. Based on clinical results, the company believes that LEVADEX has the potential to provide both fast onset of action, sustained pain relief and other migraine symptom relief in an easy-to-use and non-invasive at-home therapy.

LEVADEX is designed to incorporate the multiple beneficial mechanisms of action that allow DHE to block initiation of migraine, limit pain, reduce inflammation and stop a migraine at any point in the migraine cycle. Based on research to date, including the efficacy portion of the FREEDOM-301 trial, the company believes the unique pharmacokinetic profile of LEVADEX has the potential to effectively treat migraines, while minimizing the side effects commonly seen with DHE and other currently available medicines.

About Migraine Common symptoms of migraine include recurrent headaches, nausea, vomiting, photophobia (sensitivity to light) and phonophobia (sensitivity to sound). According to the National Headache Foundation, most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25 percent of them experience one or more attacks weekly, according to published studies. Migraine patients report that currently approved drugs do not fully meet their needs due to slow onset of action, short duration of effect, inconsistent response and unacceptable side effect profiles. The economic burden of migraine remains substantial despite existing treatments, with the direct and indirect costs of migraine in the United States estimated at over $20 billion annually.

About MAP Pharmaceuticals MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for patients suffering from conditions that are not adequately treated by currently available medicines. The Company is developing LEVADEX inhaled therapy for the
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... , Dec. 15, 2014  Stephen Squires, CEO ... Quantum Materials Corp (OTCQB:QTMM), will be speaking ... Quantum Materials (RCQM) on December 16th, 2014. The RCQM ... exotic nanomaterials in attracting top faculty and students and ... collaborate on research. "We have a ...
(Date:12/13/2014)... , Dec. 11, 2014 Research and Markets ... addition of the "Drug Injection Devices to ... http://photos.prnewswire.com/prnh/20130307/600769 As ... an expanding list of health conditions, drug developers ... simplify the administration process and increase the efficiency ...
(Date:12/13/2014)... DUBLIN , December 12, 2014 /PRNewswire/ ... ) has announced the addition of the  ... their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... dioxide (CO2) in the respiratory gasses during ... respiratory care. Capnography provides information about CO2 ...
Breaking Medicine Technology:Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 2Quantum Materials CEO Stephen Squires to Speak at Rice Center for Quantum Materials Launch 3Drug Injection Devices to 2020 2Drug Injection Devices to 2020 3Drug Injection Devices to 2020 4Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 2Global Capnography Market 2015-2019: Key Vendors are Covidien, Masimo, Philips Healthcare, Smiths Medical and Welch Allyn 3
... PRGO ; TASE) today announced that it ... of the assets of CanAm Care, a privately-held, Alpharetta, ... million in cash. The acquisition is expected to be ... The assets acquired from CanAm Care include: Dex4® hypoglycemia ...
... 2012 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: ... devices worldwide, today announced updates on new product launches for ... in 2012. N ew product ... new products, exceeding its product development goals outlined at the ...
Cached Medicine Technology:Perrigo Acquires Assets of CanAm Care for $36 Million 2Perrigo Acquires Assets of CanAm Care for $36 Million 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 2Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 3Mindray Medical Exceeds 2011 Product Development Targets and Announces Strong 2012 Pipeline 4
(Date:12/15/2014)... December 15, 2014 Main Street Dental ... is weighing in on a new study providing evidence ... the oral hygiene of children. , Sufficient enough evidence ... such as pop or juice drinks, with the onset ... however, is whether drinks listed as 100% fruit juice, ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 OutMarket ... today released “ Social Media Cheat Sheets ,” a ... community that drives results on the top ten social ... program. It helps drive awareness, engagement, and customer service. ... marketers to make an impact on new networks and ...
(Date:12/15/2014)... 14, 2014 (HealthDay News) -- Expert pilots process visual ... why they make better decisions during landings, a new ... difficult techniques for pilots to master, and 36 percent ... crashes occur during final approach and landing. Researchers ... 12 moderately experienced pilots while they were at the ...
(Date:12/15/2014)... Emergo Group, Inc., a medical device regulatory consulting ... South America, Europe, the Middle East, Asia and Australia, ... 2015 Medical Device Industry Survey. Each year, Emergo conducts ... market trends as well as regulatory and operational concerns ... , Overall prospects for medical device ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Bacteroides is becoming ... only is it much more prevalent than coliforms, it cannot ... in the environment. , Key Benefits of the new ... fecal contamination , Eliminates false positives from coliforms ... and Sensitivity , Maintain the same sampling ...
Breaking Medicine News(10 mins):Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2
... new score for predicting a person,s risk of heart ... the existing test and should be recommended for use ... Health and Clinical Excellence (NICE). The University of ... through the not-for-profit partnership QResearch, to develop the ground-breaking ...
... , ... Direct Product Evaluations and In-depth, Confidential Interviews Conducted by KLAS with Healthcare Executives and ... Market Segment. , ... Calabasas, CA (PRWEB) July 8, 2009 -- RES-Q® Healthcare Systems announced that its RES-Q ...
... Physician ... , ... July 8, 2009 -- Physician recruiting firm LocumTenens.com has announced its expansion ... specialties often referred to collectively as primary care. Traditionally a niche agency specializing ...
... TORONTO, July 8 Dyadem today announced that its ... finalist in the Information Technology category for Ernst & ... awards recognize individuals who demonstrate the entrepreneurial spirit, and ... ability to grow their businesses in the face of ...
... and the recently introduced Lindi(R) Face Wash, have been awarded ... Manufacturers and Distributors Association (ICMAD) at the sixth annual ... New York City on June 11, 2009. , ... within the beauty and personal care markets and Lindi Skin ...
... , , BETHESDA, Md., July 8 ... Care (IPC) solutions, today announced that it has expanded ... new hospital deployments and recently signed multi-year agreements to ... PatientLife System (R) . , , ...
Cached Medicine News:Health News:New heart disease risk score outperforms existing test 2Health News:RES-Q Labor Resource Management Scores the Highest Among Staff/Nurse Scheduling System Solutions Analyzed in the 2009 KLAS Mid-term Performance Review 2Health News:LocumTenens.com Expands Service Lines to Include Primary Care 2Health News:LocumTenens.com Expands Service Lines to Include Primary Care 3Health News:Dyadem CEO Kevin North Named a Finalist in Ernst & Young's 2009 Entrepreneur Of The Year Awards 2Health News:Dyadem CEO Kevin North Named a Finalist in Ernst & Young's 2009 Entrepreneur Of The Year Awards 3Health News:Skincare Industry Newcomer Shines 2Health News:GetWellNetwork Continues Growth with Eleven New Hospital Launches and Contract Signings 2Health News:GetWellNetwork Continues Growth with Eleven New Hospital Launches and Contract Signings 3
This 10 L tip was designed for the Pipetman P-2 and P-10. Its MicroPoint design and 2 L reference mark make it ideal for low volume pipetting....
... The MonoPrep LBP Processor is a ... cytology specimen collection, accessioning, processing, sampling, and ... state-of-the-art data management. The MonoPrep LBP Processor ... layers from a broad range of cytology ...
... Binding, Graduated Pipet Tips - 2l - 200l. ... referenced. Produced & packaged completely by automation. RNAse ... packaged 96 tips/rack and 10 racks/cs. AVR2 is ... racks/cs. AVR3 is the Stacked Rack packaged 96 ...
... ART Aerosol Resistant Tips offer a ... ART Tips are designed for applications such ... studies. In addition, ART Tips are excellent ... and forensic studies. ART Tips prevent aerosol ...
Medicine Products: